Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
An expert discusses how molecular profiling has become essential for most solid tumor cancers, particularly in lung cancer, where both tissue- and plasma-based testing using next-generation sequencing help identify actionable genomic targets and monitor resistance patterns.
EP: 1.Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
EP: 2.Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
EP: 3.Clinical Impact and Perspectives on Comprehensive Genomic Profiling in Advanced Lung Cancer Management
EP: 4.Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
EP: 5.What’s Next for Comprehensive Genomic Profiling in Cancer Care
Video content above is prompted by the following:
Hatim Husain, MD, emphasizes that molecular profiling has become essential for most solid tumor cancers, particularly in lung cancer treatment. For non–small cell lung cancer, comprehensive genomic testing is now standard practice to identify actionable genomic alterations that guide treatment decisions. The integration of both tissue-based testing and plasma-based next-generation sequencing provides clinicians with comprehensive molecular profiling capabilities to optimize patient care from diagnosis through treatment progression.
The discussion highlights how liquid and tissue samples work in a complementary fashion rather than as stand-alone options. When tissue samples are insufficient or turnaround time is critical, plasma testing can facilitate early identification of genomic alterations for first-line treatment decisions. Conversely, when plasma shows low tumor fraction, tissue testing becomes crucial to avoid false negative results and ensure comprehensive mutation detection for optimal patient management.
Comprehensive genomic testing serves multiple purposes throughout the patient care continuum, including up-front identification of actionable targets and genomic drivers for advanced cancers, as well as resistance monitoring at disease progression. This dual approach enables clinicians to understand why cancers may progress and identify relevant genomic changes that inform subsequent treatment strategies, ultimately improving patient outcomes through personalized, biomarker-driven therapeutic decisions.
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
